Background This study sought to define the activity and toxicity of weekly docetaxel in patients with androgen-independent prostate cancer and cancer-related pain
Introduction
In the year 2000, 31,900 men are expected to die from metastatic prostate cancer in the United States alone [1] . While initial treatment with androgen deprivation palliates this disease effectively in most men, nearly all suffer progression to androgen-independence. The dominant symptom associated with androgen-independent metastatic prostate cancer is bone pain To date, chemotherapy has had a limited role in the treatment of prostate cancer. Mitoxantrone with lowdose prednisone relieves pain due to metastatic prostate cancer in 29% of patients [2] , but does not improve survival [2, 3] . There is, therefore, an acute need for agents that can more effectively palliate the symptoms of metastatic prostate cancer and improve survival in this disease.
Docetaxel is an inhibitor of microtubule depolymenzation that reduces growth of several prostate cancer cell lines by 50% at clinically achievable concentrations [4] . Promising activity against prostate cancer is seen when the agent is combined with estramustine, another microtubule inhibitor [5] [6] [7] [8] [9] .
Less is known about the activity of this drug as a single agent in prostate cancer. Preliminary reports of two studies evaluating docetaxel 75 mg/m 2 given every 21 days have been published In 35 chemotherapy-naive patients, Picus et al demonstrated a PSA response rate, defined as the fraction of patients achieving a 50% reduction in PSA confirmed at least four weeks apart, of 46% and a 28% objective response rate in measurable disease (n -25) [10] . Friedland et al. reported a 38% PSA response rate in 16 patients, half of whom had received prior chemotherapy [11] Hematologic toxicity was common Grade 3 or 4 neutropenia was seen in 43% and 75% of patients [10, 11] . Neither study systematically evaluated the impact of chemotherapy on cancer-related symptoms and quality of life. Hematologic toxicity is not common and generally mild when docetaxel is administered weekly [12] . This study examined weekly docetaxel at 36 mg/m 2 given for six weeks of an eight-week cycle in men with symptomatic androgen-independent prostate cancer. Because the role of chemotherapy in prostate cancer remains palliative, we chose palliative benefit as the primary endpoint. Secondary endpoints included PSA response, and global quality of life. Measurable disease was assessed in those patients known to have measurable disease at study entry.
Patients and methods

Patient selection
Patients had histopathologically proven adenocarcinoma of the prostate with documented metastases, evidence of progression after medical or surgical castration, and pain that in the best judgment of the investigator, was directly related the presence of prostate cancer metastases Patients treated with combined androgen blockade had disease progression following antiandrogen withdrawal (a minimum of four weeks for flutamide and six weeks for bicalutamide) Patients had an ECOG performance status <3, life expectancy ^ 3 months, and the ability to complete pain and quality of life scales Exclusion criteria included prior chemotherapy for prostate cancer, investigational therapy within 30 days, prior malignancy (except nonmelanotic skin cancer or no evidence of disease for five years), radiotherapy within one month or radiopharmaceutical treatment within two months, WBC < 3000/mm 3 , neutrophil count < 1500/mm 3 , platelet count < 100,000/mm 3 , conjugated bilirubin > upper limit of normal (ULN), ALT >20 x ULN, alkaline phosphatase >40 x ULN or > 8 0 x ULN in patients with known bone involvement with cancer and both conjugated bilirubin and ALT in the normal range, ALT > I 5 x ULN when alkaline phosphatase >25 x ULN, and hypersensitivity to drugs formulated with polysorbate-80
All patients gave informed consent in accordance with all applicable regulations The study was approved by the Institutional Review Boards of the Oregon Health Sciences University and Salem Hospital
Evaluations
Pretreatment evaluation included medical history, physical examination with assessment of performance status, measurement of serum PSA, serum testosterone, serum biochemistry, complete blood count, and completion of a quality of life instrument Bone scan and/or CT scans confirming the presence of metastatic disease were reviewed Baseline CT scans were not required Patients' pain medications were adjusted by the study physicians to optimize pain control during a prestudy period that lasted a minimum of 7 and a maximum of 14 days The doses and medications chosen were at the discretion of the treating physician Patients who became asymptomatic with adjustment of pain medications alone were not eligible Complete blood counts were obtained weekly at the time of docetaxel administration Quality of life instruments were completed and pain medication diaries were collected every two weeks, though for the purpose of the analysis, data was abstracted every four weeks Physical examination, assessment of performance status, serum PSA, and serum biochemistry were obtained every four weeks In patients with measurable disease, measurements were repeated every eight weeks
Treatment
Docetaxel was given at a dose of 36 mg/m 2 intravenously over 15-30 minutes weekly for six consecutive weeks This cycle was repeated every e| ght weeks Premedication with dexamethasone 8 mg p o at 12 hours and I hour prior to docetaxel infusion and 12 hours after docetaxel infusion was given No other premedications were routinely used Therapy was withheld for platelet counts < 75,000/mm 3 or neutrophil count is < 1000/mm 3 The dose was reduced 25% if recovery of platelet or neutrophil count took longer than one week, if multiple consecutive doses needed to be withheld, or if patients experienced febrile neutropenia
The docetaxel dose was reduced 25% for AST elevations of 1 6-5 x ULN when bilirubin remained in the normal range and alkaline phosphatase was <5 x ULN (10 x ULN for patients whose alkaline phosphatase was 4-8 x ULN on entry) Therapy was withheld if bilirubin exceeded the normal range or alkaline phosphatase was >5x ULN (10 x ULN for patients whose alkaline phosphatase was 4-8 x ULN on entry) or AST was > 5 x ULN until recovery Those patients whose liver function tests recovered within three weeks continued treatment with a 25% dose reduction Those patients whose liver function tests did not recover within three weeks were removed from the study Assessment of outcome Palliative response, the primary endpoint, was defined as a pain response (see below) or a 50% decrease in analgesic medication use without an increase in pain maintained on two consecutive evaluations at least four weeks apart Pain response was defined as a two point reduction on the six point Present Pain Intensity (PPI) scale of the McGill-Melzack Pain Questionnaire (or compete relief if initially 1+) [13, 14] maintained on two consecutive evaluations at least four weeks apart without an increase in analgesic consumption PSA response was defined as a 50% decrease in PSA maintained on two consecutive evaluations at least four weeks apart [15] A nadir PSA was defined as the lowest value achieved that was confirmed by a second measurement equal or lower Response in bidirectionally measurable disease was assessed by standard response criteria Impact of therapy on global quality of life was measured by the EORTC core questionnaire QLQ-C30 [16, 17] obtained with permission from the EORTC (Brussels, Belgium) and QLM-P14, a module specific for prostate cancer designed according to EORTC guidelines (kindly provided by Dr David Osoba)
Analgesic medication use was monitored with a pain medication diary and an analgesic score calculated as described by Tannock et al [2] The analgesic score was calculated at baseline and every four weeks Toxicity was graded according to the revised National Cancer Institute common toxicity criteria Progression was defined as increase in the PPI by one or more integers maintained on two consecutive evaluations at least four weeks apart, an increase in analgesic score by > 50% on two consecutive measurements, a confirmed 50% increase in the PSA above baseline or above the lowest confirmed value reached, appearance of new lesions on bone scan or CTscan, or an increase of 25% or 10 cm 2 (whichever is smaller) in the sum of products of all measurable lesions over smallest sum observed Therapy was not stopped when an increase in pain was thought to be due to reasons other than progression of cancer Statistical considerations A sample size of 25 was chosen based on a two-stage study design with the goal of rejecting the regimen if the response rate is less than 10% and recommending the regimen for further study if the response rate is at least 30% The minmax design, which allows the smallest possible maximum sample size, with a = 0 05 and p = 0 20 would reject the regimen if < 2 of 15 patients respond in the first stage It would recommend the regimen for further study if at least 6 of 25 patients respond in the second stage [18] 
Results
Patient characteristics
Twenty-five men were recruited between October 1998 and March 2000. Their pretreatment characteristics are summarized in Table 1 Briefly, the median age was 72 (range 55-81). Twelve of the patients had an ECOG performance status ^2. The median PSA was 201 (range 0.6-1432). Twenty-four patients had bone metastases and five patients had measurable metastases. Fourteen patients had prior external beam radiotherapy, one " 0 -very poor, 100 -excellent had prior Strontium-89 and one received prior Samanum-153 Twenty-four patients were taking narcotic analgesics. The median follow-up from the first day of treatment is 68 weeks (range 37-99 weeks). Two patients remain on treatment, one has been on treatment for 79 weeks and the other for 37 weeks. Six patients remain alive.
Treatment
Of the planned 392 doses of docetaxel, 376 (96%) were delivered. Sixteen (4%) doses were omitted and 67 (17%) were reduced for toxicity. The median number of doses per patient was 12 (range 2-58). The total dose intensity delivered was 90% of planned dose intensity. Therapy was discontinued due to progression in 11 patients, toxicity in five patients, patient or physician preference in five patients, non-adherence with protocol procedures in one patient, and the development of a second primary cancer in one patient.
Response to therapy
Palliative response All 25 patients are evaluable for the combined endpoint of palliative response Twenty-three patients are evaluable for pain response by the PPI scale. Two patients, despite complaining of pain and requiring pain medications, reported 0 pain on their day 1 questionnaire and are therefore not evaluable for this endpoint. Twelve of 25 patients (48%, 95% CI-28%-68%) met criteria for the primary endpoint of palliative response. Five patients met this criterion by achieving the required reduction in both the PPI and analgesic score Two additional patients met this criterion by a reduction in the PP1 without a 50% reduction in the analgesic score. Five additional patients met this criterion by having a 50% reduction in the analgesic score without an increase in the PPI.
PSA response
Twenty-four of 25 patients were evaluable for PSA response One patient with a PSA of 0.6 on entry is considered not evaluable for this endpoint. Eleven of the 24 patients (46%, 95% CI of 25%-67%) met criteria for a PSA response. Six patients (25%) had a greater than 75% reduction in the PSA and four of these six patients had a greater than 90% reduction in the PSA. Two of these patients remain on treatment at week 79 and week 37. The median time to PSA progression [19] among responders was 20 weeks (range 12-87 weeks, mean 33 weeks, 95% CI 17-49 weeks). There is trend towards a correlation between PSA and pain response (chi-squareP < 0 1).
Response in measurable disease
Five patients had measurable disease. Four of these patients had lymph nodes metastases and one had metastases to the liver. Two of the patients with nodal metastases met criteria for a partial response. One had a complete disappearance of a nodal mass but is classified as a PR because the PSA did not normalize. The other had a > 50% reduction in the size of the nodal mass. Both patients had profound reduction in the PSA, 95% and 98%. One of the two progressed after 87 weeks, while the other remains a responder and is in the 79th week of treatment. Those patients who did not meet criteria for response included one patient with nodal metastases whose measurable disease remained stable for 24 weeks, a second patient whose nodal mass remained stable for eight weeks, and a patient with a liver metastasis who progressed within eight weeks of starting therapy. 
Quality of life
In the absence of a control arm, quality of life should be viewed as hypothesis-generating and findings should be confirmed in phase III studies. There was no difference in overall quality of life or any QLQ-C30 or QLM-P14 domain at baseline between those patients who subsequently responded to treatment and those who did not (Table 2) .
Change in QLQ-C30 or QLM-P14 domains after one and two cycles of therapy were examined within the groups of patients remaining on study by subtracting patients' own pretreatment scores from those obtained after one and two cycles of treatment (Table 3) . P-values reported were not corrected for multiple comparisons in order to reduce the risk of type II error After cycle 1, pain is reduced significantly and there is a trend towards an improvement in nausea and vomiting, pain impact on mobility, and pain relief. There is also a trend towards a worsening of dyspnea. After cycle 2, pain remains improved significantly, there is a trend towards improvement in pain impact on mobility and global quality of life, and a trend towards a worsening of dyspnea A change of 10 points or greater in a quality of life domain is thought to be important because it is easily perceived by patients and may be clinically important [20, 21] Figure 1 summarizes the fraction of patients who reported at least a 10-point change in those domains for which the mean change was associated with a P-value <0.1 When the analysis was limited to PSA responders, 11 patients were available after cycle 1 and 10 after cycle 2, therefore statistical power was modest. Global quality of life improved by a mean of 9.4 points (P = 0.04) after cycle 1 and 22 5 (P = 0.02) after cycle 2. Pain was improved by 24.2 points after cycle 1 (P = 0.01) and by 22.5 points [P = 0 11) after cycle 2.
Survival
Six patients remain alive The median survival of the entire cohort was 39 weeks (range 18-89+ weeks). This survival reflects the advanced disease state and compromised performance status seen in this patient population selected for significantly symptomatic disease.
Toxicity
Treatment was generally well tolerated. There was no treatment-related mortality. Over all, 25% of patients experienced a grade 3 or 4 hematologic toxicity and Figure I Percentage of patients reporting a I0-point or greater QOL domains Only domains whose mean is changed after one and/or two cyles of treatment with a /'-value < 0 I are shown 36% of patients experienced a grade 3 non-hematologic toxicity. Twenty percent of patients discontinued treatment because of toxicity, 16% because of a grade 3 or 4 toxicity. While 16% of patients experienced a grade 3 or 4 neutropenia, none suffered an episode of neutropenic fever. Anemia was common with 40% of patients experiencing grade 2 or 3 anemia. All of these patients had grade 1 anemia on study entry. The most common grade 2 or higher non-hematologic toxicity was diarrhea, which occurred in 20% of patients. Details of treatment-related toxicity are summarized in Table 4 .
Discussion
In this study, single agent weekly docetaxel at 36 mg/m 2 was given to patients with advanced, symptomatic androgen-independent prostate cancer. Nearly half of these patients had an ECOG performance status of 2 or 3 on entry. In this challenging patient population, treatment was generally well tolerated Twenty percent of patients stopped therapy due to toxicity, 25% of patients experienced a grade 3 or 4 hematologic toxicity, and 36% of patients experienced a grade 3 non-hematologic toxicity. We were able to deliver 90% of the planned dose intensity. In this patient population, weekly docetaxel was active regardless of the yardstick applied to measure activity. Palliative response rate was 48%, PSA response rate was 46% and two of five patients with measurable disease had a partial response. Activity reported in phase II studies must, however, be viewed as preliminary. Docetaxel's true worth in the treatment of advanced prostate cancer will be determined in phase III studies The contribution of dexamethasone to the activity of weekly docetaxel is unknown. Corticosteroids administered daily are known to produce greater than 50% reduction of PSA in 22-61% of patients with androgenindependent prostate cancer [2, 3, 13, 22-25] Dexamethasone 20 mg given orally every six hours for three doses administered every three weeks does not reduce the PSA in patients with AIPC [26] . Because steroids reduce the adverse effects of docetaxel [27] , it would be difficult to recommend a randomized study of docetaxel with and without dexamethasone. A trial of singleagent dexamethasone administered weekly should be considered.
In addition to conventional endpoints, this study included a rigorous analysis of quality of life. While a definitive analysis of the impact of docetaxel on quality of life would require a larger, randomized study, results seen in this study support the findings of the primary endpoint and provide an additional dimension to the analysis of adverse events. Notably, multiple measures of pain of the QLQ-C30 and QLM-P14 confirm that the study population experienced significant relief of pain with therapy. A trend towards an improvement in global quality of life is seen in those patients who completed two cycles of therapy, and significant gains in global quality of life were seen in PSA responders after both cycle 1 and cycle 2. Interestingly, nausea and vomiting appeared to improve with therapy when compared to pretreatment levels. While the reason for this is uncertain, 40% of patients on the study were able to reduce their narcotic use by half or more. Narcotic use may have been contributing to nausea prior to therapy and reduction in narcotic-requirements may have contributed to a reduction in nausea. The only QOL domain that showed significant worsening was dyspnea. While pleural effusions were detected in two patients (one grade 1 and one grade 3), these alone would not explain this increase in dyspnea. Chest X-rays were not routinely obtained on this study so it is possible that additional patients experienced undetected pleural effusions.
Newer chemotherapy regimens for prostate cancer commonly include a taxane and estramustine. The combination was developed after a favorable interaction between these agents was demonstrated in preclinical models of prostate cancer [28] . The demonstration of a 53% PSA response rate for the combination of paclitaxel and estramustine [29] after single agent paclitaxel was shown to have a 4% PSA response rate [30] reinforced interest in these combinations. Indeed, initial clinical trials ofdocetaxel in prostate cancer included estramustine. The results of this trial, as well as those seen with docetaxel dosed on a 21-day schedule [10, 11] cannot measure the relative contributions of docetaxel and estramustine to the activity of combination therapy. They do, however, demonstrate that docetaxel alone has significant activity in androgen-independent prostate cancer. The activity appears sufficient for single agent docetaxel to be a viable building block for future novel combinations. A randomized study would be necessary to examine the contribution of estramustine in docetaxel-containing combinations In conclusion, weekly docetaxel given on this schedule is active and well tolerated in men with advanced, symptomatic, androgen-independent prostate cancer. Activity was seen by all relevant measures including palliation of symptoms, PSA, and measurable disease. Randomized studies are needed to further evaluate the value of docetaxel in the treatment of androgen-independent prostate cancer
